Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Abbott Vascular

Division of Abbott Laboratories Inc.
www.abbottvascular.com

Latest From Abbott Vascular

Class I Recall On Abbott Coronary Catheters

The US FDA has announced a high-risk class I recall on two makes of coronary dilation catheters made by Abbott Vascular because a manufacturing issue could lead to difficulties deflating the balloon. The catheters have been linked to 13 complaints and one death.

Recalls Safety

TCT 2019: A Preview Of Late-Breaking Trials; Analyst Expectations

Interventional cardiologists can expect important updates on transcatheter valves and drug-eluting stents during this year's late-breaking trials presented at the annual Transcatheter Cardiovascular Therapeutics meeting next week. They include updates from Edwards Lifesciences, Medtronic, Boston Scientific and Abbott.

Clinical Trials Cardiovascular

TCT 2018: New ABSORB Trial Data Fails To Impress

Abbott's defunct Absorb BVS stent's efficacy is noninferior to that of the Xience metallic everolimus-eluting stent, new data presented at the Transcatheter Cardiovascular Therapeutics (TCT) conference in San Diego show. But the risk of thrombotic events was still higher with Absorb. This prompted a discussion among panelists whether bioresorbable stents should still be investigated, given the availability of newer-generation drug-eluting stents, which have shown to be safer.

Clinical Trials Research & Development

TCT 2018: Abbott Expects COAPT Results To Support Expanding MitraClip's Indication

Data presented at the Transcatheter Cardiovascular Therapeutics conference Sept. 23 in San Diego will support expanding the label of Abbott's MitraClip mitral valve repair device to include secondary, or functional, mitral regurgitation, a company executive tells Medtech Insight. In the COAPT trial, MitraClip reduced the two-year rate of heart-failure hospitalization and all-cause mortality in patients with heart failure and moderate-to-severe or severe secondary mitral regurgitation.

Clinical Trials Innovation
See All

Company Information

  • Industry
  • Medical Devices
    • Implantable Devices
    • Surgical Equipment & Devices
      • Minimally or Less Invasive
  • Therapeutic Areas
  • Cardiovascular
  • Alias(es)
  • Abbott Vascular Devices
  • Ownership
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Abbott Laboratories Inc.
  • Senior Management
  • Contact Info
  • Abbott Vascular
    Phone: (408) 845-3000
    3200 Lakeside Dr.
    Santa Clara, CA 95054-2807
    USA
UsernamePublicRestriction

Register